Impact of CES1 Genotype on Metabolism of Methylphenidate
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether differences in the gene coding for the
liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of
methylphenidate, a CES1 dependent drug.
Phase:
Phase 4
Details
Lead Sponsor:
Bispebjerg Hospital
Collaborators:
Duke University Mental Health Centre Sct. Hans (Denmark) The Leiden Academic Center for Drug Research (LACDR) The Ministry of Science, Technology and Innovation, Denmark University of Copenhagen